Aliakbarian Mohsen, Khodashahi Rozita, Sabbagh Mahin Ghorban, Rezayat Kambiz Akhavan, Khodashahi Mandana, Khaleghi Ebrahim, Moghaddam Maliheh Dadgar, Razmkhah Baran, Nazar Mahdi Nik, Sheikhi Nadia
Hepatopancreatobiliary & Transplant Surgery, Mashhad Transplant Research Center, Montaserieh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Surgical Oncology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Drug Saf. 2023;18(1):15-22. doi: 10.2174/1574886317666220304122420.
There are various vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, vaccination may lead to some complications.
This study aimed to investigate the complications of transplant recipients who received the Sinopharm COVID-19 vaccine.
This was a retrospective cross-sectional study conducted among 667 transplant recipients (211 liver transplant recipients and 456 kidney transplant recipients) who received the Sinopharm COVID-19 vaccine from March to August 2021 and had medical records in Montaserieh Hospital, affiliated to Mashhad University of Medical Sciences, Mashhad, Iran. The demographic and clinical information, as well as patient's symptoms after each dose of the vaccine, were recorded.
Only 16.8% and 13.7% of the patients experienced some symptoms following the first and second doses of the Sinopharm vaccine, respectively. No significant difference was observed between patients younger than 50 years and those aged 50 years and over in terms of the complication rate of the Sinopharm vaccine (P>0.005). Vaccine failure was reported in 10% of the cases; however, the mortality rate due to infection with the Delta variant of COVID-19 in this population was reported to be 0.7%.
Based on the obtained results, adverse reactions of the Sinopharm COVID-19 vaccine are generally mild, predictable, and non-life-threatening both in the first and second doses. Vaccine failure was reported in 10% of the cases; however, mortality due to infection with the Delta variant of COVID-19 was reported in less than 1% of the cases.
有多种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗。然而，接种疫苗可能会导致一些并发症。
本研究旨在调查接种国药集团新冠疫苗的移植受者的并发症。
这是一项回顾性横断面研究，研究对象为2021年3月至8月在伊朗马什哈德医科大学附属蒙塔塞里耶医院接种国药集团新冠疫苗且有病历记录的667名移植受者（211名肝移植受者和456名肾移植受者）。记录了人口统计学和临床信息，以及每次接种疫苗后患者的症状。
分别只有16.8%和13.7%的患者在接种第一剂和第二剂国药疫苗后出现了一些症状。在国药疫苗的并发症发生率方面，50岁以下患者和50岁及以上患者之间未观察到显著差异（P>0.005）。10%的病例报告了疫苗接种失败；然而，据报道该人群中因感染新冠病毒德尔塔变异株导致的死亡率为0.7%。
根据所得结果，国药集团新冠疫苗的不良反应在第一剂和第二剂中通常都很轻微、可预测且不危及生命。10%的病例报告了疫苗接种失败；然而，因感染新冠病毒德尔塔变异株导致的死亡率在不到1%的病例中被报告。
